Applications of AI in healthcare, including medical diagnostics, drug discovery, patient care solutions, and biotechnology research.
Bristol Myers Squibb has entered a strategic agreement with Anthropic to deploy Claude Enterprise across its global operations, integrating AI agents into research, development, manufacturing, and commercial workflows for over 30,000 employees.
MemorialCare has implemented Cleerly’s FDA-cleared AI coronary analysis technology across its hospitals, making Long Beach Medical Center the first in Los Angeles County to offer AI-based plaque quantification for heart disease assessment.
IGEL and Zscaler have introduced new healthcare security blueprints to help organizations secure distributed care delivery environments. The guidance, presented at HIMSS26 Europe, combines IGEL's endpoint platform with Zscaler's Zero Trust Exchange to protect clinical systems and patient data.
Araceli Biosciences has introduced Endeavor Live Cell, an imaging system designed to enable rapid kinetic imaging for large-scale screening in AI-driven drug discovery workflows.
Flywheel announced an integration with AWS HealthImaging to streamline the management of medical imaging data for clinical trials, research, and AI development. The collaboration enables organizations to create standardized, analysis-ready imaging datasets across regulated and exploratory workflows.
NeuroDiscovery AI has introduced NeuroTerminal, a platform built for neurology research that integrates clinical trial management, real world data, and medical affairs to speed up patient recruitment and therapy access.
Biotia has introduced BIOTIA-DX Resistance, an antimicrobial resistance profiling tool now integrated into its CLEP-approved BIOTIA-ID Urine Test for clinical use across the U.S. The platform provides rapid resistance prediction to guide treatment for complicated urinary tract infections.
Open Medicine has launched a new platform called Living Algorithms, designed to help clinicians make faster and more informed cancer treatment decisions by sharing continuously updated, interactive treatment pathways authored by leading physicians.
A new report from 5WPR shows that Novo Nordisk and Eli Lilly account for nearly all GLP-1 citations across AI platforms like ChatGPT, Claude, and Perplexity, with their brands controlling 57% of total mentions in the weight loss category.
Sino Biological has launched the XPressMAX Cell Free Protein Synthesis Kit, enabling protein and antibody synthesis in three hours to support AI driven high throughput screening for antibody drug discovery.
28bio has launched CNS-3D Inflammatory Organoids, a human brain tissue model designed to test the efficacy of anti-inflammatory drugs in central nervous system diseases. The organoids combine neurons, astrocytes, and microglia to simulate inflammation and assess therapeutic responses.
Genedata has introduced Genedata Vico, an AI based platform developed with major pharmaceutical partners to accelerate Chemistry, Manufacturing, and Controls (CMC) processes and improve regulatory readiness.
Verato has announced the Verato Identity Network, a shared identity infrastructure designed to help healthcare organizations accurately identify individuals across systems and partners, enabling AI adoption and interoperability.
A large-scale study from GlycanAge and Circulate Health has confirmed IgG glycans as predictive of all-cause mortality and responsive to therapeutic plasma exchange, marking a significant advance in biological age measurement.
Azra AI has appointed oncology strategist Jessica Turgon to its Board of Directors. Turgon brings decades of experience in oncology operations and strategy, including leadership roles at Siemens Healthineers and ECG Management Consultants.
Century Health has raised $5 million in an oversubscribed seed round led by Origin Ventures to expand its AI platform CHARM, which automates the curation of clinical data with 97 percent accuracy.
Vi has released a suite of AI agents for healthcare, life sciences, and wellness enterprises, integrated across its Activate, Engage, and Operate platforms. The company also completed a $145 million transaction, valuing it at $1.64 billion.
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has announced eight new projects worth $9.7 million to advance biopharma manufacturing and workforce development. The projects focus on AI-based process optimization, real-time analytics, and training initiatives to strengthen the U.S. talent pipeline.
Mayo Clinic and Bayesian Health have co-developed an AI system that identifies hospitalized patients who may benefit from palliative care earlier in their stay, aiming to improve patient outcomes and reduce readmissions.
ACROBiosystems held its Innovation Day in Zurich, where experts discussed advances in biologics development and translational science. The company presented its AI platform for protein engineering, featuring examples of optimized cytokines and antibodies.
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
